Do we underestimate pulmonary tuberculosis and coronavirus disease 2019 co-infection? a brief review of a rare case

SARS-CoV-2 Shedding in Dialysis Patients With COVID-19

ISTH interim guidance on recognition and management of coagulopathy in COVID‐19: A comment

The Role of Flexible Bronchoscopy in Swab-negative Patients During the SARS-CoV2 Pandemic.

ISTH interim guidance on recognition and management of coagulopathy in COVID‐19

Objective: The diagnosis and treatment of coronavirus disease-2019 (COVID-19) infection may be delayed in pregnant women because of the non-specific symptoms and limited application of the necessary radiological tests. The aim of this study was to compare the serum D-dimer, fibrinogen, and platelet levels in pregnant patients with COVID-19 symptoms and polymerase chain reaction (PCR) positivity or PCR negativity. Material and Methods: The study included 100 pregnant women who presented at the Gynaecology and Obstetrics Clinic of Tokat State Hospital between April 2020 and December 2020 with symptoms of COVID-19 infection (fever, cough, shortness of breath). Half of the patients were COVID-19 PCR positive and half were negative. The groups were compared in respect of age, gravida, gestational week, COVID-19 symptoms (fever, cough, shortness of breath), serum D-dimer, fibrinogen, and platelet values. Results: The serum D-dimer and fibrinogen levels were determined to be significantly higher in the PCR positive group than in the PCR negative group (1.78±1.04 mg/L vs. 0.97±0.48 mg/L, p=0.001 and 348.02±84.69 g/mL vs. 265.84±92.10 g/mL, p=0.001, respectively). The complaints of cough and shortness of breath were determined to be significantly higher in the PCR positive group than in the PCR negative group (p=0.001, p=0.008). Conclusion: Routine measurements of serum D-dimer and fibrinogen levels in pregnant patients presenting with COVID-19 symptoms may be useful in early diagnosis and therefore an earlier start to treatment, without performing a COVID-19 PCR test. The presence of cough and shortness of breath in pregnant patients is more important than fever in the management of COVID-19 infection.

COVID‐19 associated coagulopathy and thromboembolic disease: Commentary on an interim expert guidance

Emergence of institutional antithrombotic protocols for coronavirus 2019

Organ transplantation during the COVID-19 pandemic: Making the best patient care decision.

Early effects of unfractionated heparin on clinical and radiological signs and D-dimer levels in patients with COVID-19 associated pulmonary embolism: An observational cohort study

Deep venous thrombosis in a non-critically ill patient with novel COVID-19 infection

Lung health in Africa: challenges and opportunities in the context of COVID-19.

BackgroundInformation on tuberculosis (TB) and coronavirus disease 2019 (COVID-19) is still limited. The aim of this study was to describe the features of the TB/COVID-19 co-infected individuals from a prospective, anonymised, multicountry register-based cohort with special focus on the determinants of mortality and other outcomes.MethodsWe enrolled all patients of any age with either active TB or previous TB and COVID-19. 172 centres from 34 countries provided individual data on 767 TB-COVID-19 co-infected patients, (>50% population-based).ResultsOf 767 patients, 553 (74.0%) out of 747 had TB before COVID-19 (including 234 out of 747 with previous TB), 71 (9.5%) out of 747 had COVID-19 first and 123 (16.5%) out of 747 had both diseases diagnosed within the same week (n=35 (4.6%) on the same day). 85 (11.08%) out of 767 patients died (41 (14.2%) out of 289 in Europe and 44 (9.2%) out of 478 outside Europe; p=0.03): 42 (49.4%) from COVID-19, 31 (36.5%) from COVID-19 and TB, one (1.2%) from TB and 11 from other causes. In the univariate analysis on mortality the following variables reached statistical significance: age, male gender, having more than one comorbidity, diabetes mellitus, cardiovascular disease, chronic respiratory disease, chronic renal disease, presence of key symptoms, invasive ventilation and hospitalisation due to COVID-19. The final multivariable logistic regression model included age, male gender and invasive ventilation as independent contributors to mortality.ConclusionThe data suggest that TB and COVID-19 are a “cursed duet” and need immediate attention. TB should be considered a risk factor for severe COVID disease and patients with TB should be prioritised for COVID-19 preventative efforts, including vaccination.

Tuberculosis (TB) is a global pandemic and is one of the top 10 causes of death worldwide as well as the leading cause of death from a single infectious agent. It can cause a wide array of complications including peripheral neuropathy. In addition to TB pandemic the recent pandemic of coronavirus disease 2019 (COVID-19) has led to an increased interest in the co-infection of TB patients and COVID-19 and whether TB increases risk for COVID-19 and its role in causing severity of disease and vice-versa. This case report discusses about a young cachectic man who was found to have bilateral foot-drop under the setting of TB with co-infection of COVID-19 later confirmed to be axonal neuropathy on nerve conduction study. The report highlights the importance of differential diagnosis of TB in COVID-19 patients as well as the consideration of TB in a patient with peripheral neuropathy after nutritional causes have been ruled out.

The aim of this review is to examine the effects of COVID-19 on Tuberculosis (TB) management and to highlight evidence of the extent of TB and COVID-19 co-infection. Current findings on TB and COVID-19 have been identified using six databases: Pubmed, Science Direct, Pubmed Central, MedXRiv, Wiley, and Google Scholar. This search in literature was conducted up to 8 May 2020. We included five studies that met the selection criteria. These selected studies have been performed in regions having various demographic characteristics including developed and developing countries, mainly China. The total number of participants in each study ranged from 24 to 203. The case fatality rate of patients with TB and COVID-19 co-infection was found to be high (6/49; 12.3 percent) while a combined diagnosis of TB and COVID-19 was found in 9/49 patients. This condition is linked to several complications, manifested as the need for ex novo oxygen supply, pneumothorax, and extreme hypoxia. Researches on BCG vaccination have shown that countries without vaccination policy are more likely to be seriously affected than those with BCG vaccination programs. COVID-19 infection in patients with TB or the lack of sufficient BCG vaccination may be associated with higher detrimental consequences, including mortality.

Hypercoagulability and Anticoagulation in Patients With COVID-19 Requiring Renal Replacement Therapy